产品说明书
Dexrazoxane
 |
同义名 : | ICRF-187;ADR-529;Zinecard. Foreign brand names: Cardioxane Savene.;US brand names: Totect;Cardioxane;Cardioxan;Zinecard;Totect®;NSC-169780 |
| CAS号 : | 24584-09-6 | |
| 货号 : | A170417 | |
| 分子式 : | C11H16N4O4 | |
| 纯度 : | 99%+ | |
| 分子量 : | 268.269 | |
| MDL号 : | MFCD00866449 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 25 mg/mL(93.19 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Dexrazoxane, a derivative of the powerful metal-chelating agent ethyl enediamine tetra acetic acid, is a cardioprotective agent. Dexrazoxane is well-tolerated, with myelosuppression being the dose-limiting toxicity in Phase I trials[3]. As a single agent, dexrazoxane inhibited synchronized cultures of P. falciparum in human erythrocytes only at suprapharmacologic concentrations (> 200 microM). In combination with desferrioxamine B, dexrazoxane in pharmacologic concentrations (100-200 microM) moderately potentiated inhibition by approximately 20%. In contrast, pharmacologic concentrations of dexrazoxane (50-200 microM) as a single agent inhibited the progression of P. yoelli from sporozoites to schizonts in cultured mouse hepatocytes by 45 to 69%[4]. Dexrazoxane preserved cardiac function without compromising EFS (event-free survival) and OS (overall survival) or increasing noncardiac toxicities[5]. Dexrazoxane might exert a cardioprotective effect against doxorubicin-induced cardiomyocyte apoptosis by regulating the expression of miR-17-5p/PTEN cascade[6]. Dexrazoxane may protect against RIHD (radiation-induced heart disease) by suppressing apoptosis and oxidative stress in cardiomyocytes[7]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02786719 | Neuroblastoma | Not Applicable | Recruiting | June 2019 | United States, California ... 展开 >> Rady Children's Hospital Recruiting San Diego, California, United States, 92123 Contact: Laura Conner 858-966-5983 LConner@rchsd.org Principal Investigator: Peter Zage, MD United States, Texas Texas Children's Hospital Recruiting Houston, Texas, United States, 77030 Contact: Sarah Whittle, MD, BA 832-822-4242 sbwhittl@txch.org 收起 << |
| NCT00077285 | Sarcoma | Phase 2 | Active, not recruiting | October 2019 | United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 << |
| NCT00400946 | Drug/Agent Toxicity by Tissue/... 展开 >>Organ Leukemia 收起 << | Phase 3 | Active, not recruiting | June 2019 | United States, Massachusetts ... 展开 >> Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Albert Einstein Cancer Center at Albert Einstein College of Medicine Bronx, New York, United States, 10461 Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center New York, New York, United States, 10032 James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States, 14642 United States, Rhode Island Hasbro Children's Hospital Providence, Rhode Island, United States, 02903 United States, Virginia INOVA Fairfax Hospital Fairfax, Virginia, United States, 22031 Canada, Ontario McMaster Children's Hospital at Hamilton Health Sciences Hamilton, Ontario, Canada, L8N 3Z5 Canada, Quebec Hopital Sainte Justine Montreal, Quebec, Canada, H3T 1C5 Centre de Recherche du Centre Hospitalier de l'Universite Laval Sainte Foy, Quebec, Canada, GIV 4G2 Puerto Rico San Jorge Children's Hospital Santurce, Puerto Rico, 00912 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.73mL 0.75mL 0.37mL |
18.64mL 3.73mL 1.86mL |
37.28mL 7.46mL 3.73mL |
| 参考文献 |
|---|